Orphazyme A/S - ORPH Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Orphazyme A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORPH

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Orphazyme A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ORPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Orphazyme A/S. This rating has held steady since June 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2021GuggenheimDowngradeNeutral ➝ SellMedium
6/18/2021CowenDowngradeOutperform ➝ Market PerformLow
3/30/2021Bank of AmericaDowngradeNeutral ➝ Underperform$13.00 ➝ $5.00High
10/26/2020Bank of AmericaInitiated CoverageBuy$13.00High
10/26/2020GuggenheimInitiated CoverageBuy$27.00Medium
(Data available from 12/7/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Orphazyme A/S logo
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.43
Low: $0.57
High: $2.21

52 Week Range

Now: N/A

Volume

941,400 shs

Average Volume

1,371,185 shs

Market Capitalization

$30.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Orphazyme A/S?

The following Wall Street research analysts have issued reports on Orphazyme A/S in the last twelve months:
View the latest analyst ratings for ORPH.

What is the current price target for Orphazyme A/S?

0 Wall Street analysts have set twelve-month price targets for Orphazyme A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Orphazyme A/S in the next year.
View the latest price targets for ORPH.

What is the current consensus analyst rating for Orphazyme A/S?

Orphazyme A/S currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ORPH.

What other companies compete with Orphazyme A/S?

How do I contact Orphazyme A/S's investor relations team?

Orphazyme A/S's physical mailing address is OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200. The company's listed phone number is 45-2898-9055 and its investor relations email address is [email protected] The official website for Orphazyme A/S is www.orphazyme.com. Learn More about contacing Orphazyme A/S investor relations.